The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

The U.S. Centers for Disease Control and Prevention on Friday upheld the role of vaccines in offering protection against ...

Tariffs should not influence decisions at Indian drug companies, Cipla's top executive said on Friday, as the industry braces ...

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Shares of Biogen Inc. BIIB slipped 2.07% to $140.49 Wednesday, on what proved to be an all-around mixed trading session for ...

As one study finds, traditional titles are leading enterprise Gen AI adoption and the Chief AI Officer role continues to grow ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to take a look at where Biogen Inc.

The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its ...

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...

The change in leadership comes shortly after Indivior warned that it is expecting a sharp decline in its revenues in 2025, ...